Skip to main content

Table 5 Association between biochemical markers C1M, C2M, C3M, CRPM, and hsPRO-C2 at baseline and changes in BML imaging features from baseline to 24 months

From: Association of biochemical markers with bone marrow lesion changes on imaging—data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium

BMLs

Serum C1M

Serum C2M

Serum C3M

Serum CRPM

Serum hsPRO-C2

Maximum size

0.99

0.95

0.11

0.96

1.02

P = 0.911

P = 0.523

P = 0.467

P = 0.539

P = 0.825

(0.84, 1.17)

(0.79, 1.12)

(0.91, 1.24)

(0.83, 1.10)

(0.85, 1.23)

Number of subregions

1.13

1.12

1.08

0.97

1.06

P = 0.147

P = 0.206

P = 0.328

P = 0.631

P = 0.543

(0.96, 1.34)

(0.34, 1.32)

(0.83, 1.26)

(0.84, 1.11)

(0.88, 1.28)

  1. BMLs, bone marrow lesions; OR, odds ratio; 95% CI, 95% confidence interval; C1M, C2M, C3M, serum type I, type II and type III collagen degradation mediated by matrix metalloproteinase (MMP) cleavage; hsPRO-C2, serum propeptide of type IIb collagen; CRPM, serum metabolite of C-reactive protein
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us